Factor XIII: The cement of the heart after myocardial infarction?

European Heart Journal

Volumn 29, Issue 4, 2008, Pages 427-428

  Vanhoutte, Davy ^a   Heymans, Stephane ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 13; CEMENT; COLLAGEN; FIBRINOGEN; FIBRONECTIN; OSTEONECTIN; OSTEOPONTIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; VASCULOTROPIN; VITRONECTIN;

ANGIOGENESIS; CLINICAL ASSESSMENT; CLINICAL PRACTICE; EDITORIAL; ENZYME ACTIVITY; HEALING; HEART DILATATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE BIOPSY; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATORY CELL; ISCHEMIC HEART DISEASE; MOLECULAR IMAGING; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; FACTOR XIII; FIBRINOLYTIC AGENTS; HEART RUPTURE, POST-INFARCTION; HUMANS; MYOCARDIAL INFARCTION; TRANSGLUTAMINASES; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING; WOUND HEALING;

EID: 39349096194     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehm610     Document Type: Editorial

References (9)

1. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-171.
2. Griffin M, Casadio R, Bergamini CM. Transglutaminases: nature's biological glues. Biochem J 2002;368:377-396.
3. Woodiwiss AJ, Tsotetsi OJ, Sprott S, Lancaster EJ, Mela T, Chung ES, Meyer TE, Norton GR. Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. Circulation 2001;103:155-160.
4. Vanhoutte D, Schellings MW, Gotte M, Swinnen M, Herias V, Wild MK, Vestweber D, Chorianopoulos E, Cortes V, Rigotti A, Stepp MA, Van de Werf F, Carmeliet P, Pinto YM, Heymans S. Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation 2007;115:475-482.
5. Nahrendorf M, Hu K, Frantz S, Jaffer FA, Tung CH, Hiller KH, Voll S, Nordbeck P, Sosnovik D, Gattenlohner S, Novikov M, Dickneite G, Reed GL, Jakob P, Rosenzweig A, Bauer WR, Weissleder R, Ertl G. Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodelling in mice with myocardial infarction. Circulation 2006;113:1196-1202.
6. Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res 1999;94:271-305.
7. Nahrendorf M, Aikawa E, Figueiredo JL, Stangenberg L, van den Borne S, Blankesteijn WM, Sosnovik D, Jaffer FA, Tung CH, Weissleder R. Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodeling: implications for FXIII therapy and antithrombin use in myocardial infarction. Eur Heart J 2008;29:445-454. doi:10.1093/eurheartj/ ehm558.
8. Schellings MW, Pinto YM, Heymans S. Matricellular proteins in the heart: possible role during stress and remodelling. Cardiovasc Res 2004;64:24-31.
9. Lepor NE. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors. Rev Cardiovasc Med 2007;8 Suppl 3:S9-S17.